ArticleBlood advances2026
Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
abstractAllogeneic hematopoietic cell transplantation (HCT) and autologous hematopoietic stem cell-based gene therapies are potentially curative for sickle cell disease (SCD). Although most patients experience resolution of overt clinical symptoms associated with SCD with donor-dominant myeloid chimerism after undergoing HCT or the induction of a substantial amount of alternative hemoglobin (Hb) after gene therapy (GT), whether the underlying subclinical physiology is normalized in these individuals is unknown. One approach to evaluating the underlying physiology is to characterize the blood rheology of patients after they receive these therapies. We assessed the rheology of 123 blood samples from 69 patients, of whom 43 underwent HCT (32 from matched related donors; 11 from haploidentical donors) and 11 received GT. The results were compared to those for patients treated with hydroxyurea with optimum fetal Hb response (HUOptimum; n = 15). Median rheology parameters of recipients of HCT from donors with sickle cell trait (HbAS) were superior to those of GT recipients (elongation index under hypoxia [EImin]: 0.6 vs 0.31; point of sickling [PoS]: 0 vs 26.21) and of the HUOptimum cohort (EImin, 0.6 vs 0.15; PoS, 0 vs 36.2; percentage of dense red blood cells, 0.9 vs 4.9; P< .05 for all comparisons). Results for the GT and HUOptimum groups were comparable (P> .05). Given the substantial number of patients with abnormal rheology and the associations between rheology and SCD-related complications, rheology tests may be included in the follow-up care for HCT and GT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.